research The Spectrum of Cutaneous Adverse Events During Encorafenib and Binimetinib Treatment in B-Rapidly Accelerated Fibrosarcoma-Mutated Advanced Melanoma
The combination of encorafenib and binimetinib caused few skin issues.
Search
for
Sort by
Research
16 / 16 results
research BAYONET Trial: Staged Combination With Encorafenib, Binimetinib, Plus Cetuximab Following Encorafenib Plus Cetuximab for BRAF V600E-Mutant Metastatic Colorectal Cancer
The combination treatment showed a higher response rate but no significant survival benefits.
research Pathogenesis and Treatment Options for Chemotherapy-Induced Alopecia: A Systematic Review
Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.
research Alopecia in Association with Malignancy: A Review
Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.
research Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research Adverse Hair Reactions to New Targeted Therapies for Cancer
New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
research Mesotherapy with Dutasteride and Minoxidil in the Treatment of Androgenetic Alopecia
Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.
research Melanotic Pigmentation in Excisional Scar of Melanoma Patient Who Received BRAF and MEK Inhibitors
Patients with melanoma who saw dermatologists and were from higher-income areas were more likely to have follow-up visits, which was linked to lower mortality.
research Melanoma Follow-Up and Mortality: A Large-Scale Study of Medicare Patients
Regular follow-up visits, especially with dermatologists, can lower death rates for melanoma patients, with socioeconomic factors also affecting outcomes.
research Melanoma Prognosis in the United States: A State-Based Analysis of Associated Factors
Melanoma survival rates vary by state and are better where incomes are higher, more people have health insurance and education, and there are more dermatologists.
research Development of a Non-Parametric Population Pharmacokinetics Model and Bayesian Estimator for Tacrolimus in Tunisian Renal Transplant Patients
The model and estimator can predict drug exposure in kidney transplant patients well.
research Prevention And Management Of Dermatological Toxicities Related To Anticancer Agents: ESMO Clinical Practice Guidelines
Early intervention and tailored management can reduce skin side effects from cancer treatments.
research Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution, And Tumor-Initiating Cells
Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.
research Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
The study found key factors in the cause of hidradenitis suppurativa, its link to other diseases, and identified existing drugs that could potentially treat it.
research Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies
Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.
research Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.